Brookstone Capital Management Grows Stock Holdings in Harrow, Inc. $HROW

Brookstone Capital Management boosted its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 232.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 45,775 shares of the company’s stock after purchasing an additional 32,009 shares during the period. Brookstone Capital Management owned about 0.12% of Harrow worth $2,205,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Quarry LP bought a new position in shares of Harrow during the 1st quarter valued at $32,000. Raymond James Financial Inc. purchased a new stake in Harrow during the second quarter valued at $48,000. State of Wyoming bought a new position in Harrow in the first quarter valued at about $97,000. Tower Research Capital LLC TRC boosted its position in Harrow by 345.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock worth $103,000 after purchasing an additional 2,615 shares during the last quarter. Finally, Strs Ohio purchased a new position in Harrow in the first quarter worth about $149,000. Institutional investors own 72.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. LADENBURG THALM/SH SH upped their price target on shares of Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. HC Wainwright upped their target price on shares of Harrow from $64.00 to $69.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research note on Wednesday, October 8th. B. Riley reissued a “buy” rating and set a $74.00 price objective (up previously from $70.00) on shares of Harrow in a research report on Wednesday, October 1st. Finally, Lake Street Capital upped their price objective on Harrow from $42.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $71.43.

Harrow Price Performance

Shares of NASDAQ:HROW opened at $50.09 on Friday. The company has a market capitalization of $1.86 billion, a P/E ratio of -500.85 and a beta of 0.07. Harrow, Inc. has a 1-year low of $20.85 and a 1-year high of $51.30. The firm’s 50 day simple moving average is $41.78 and its two-hundred day simple moving average is $38.78. The company has a debt-to-equity ratio of 5.21, a current ratio of 2.72 and a quick ratio of 2.52.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Monday, November 10th. The company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.22 by $0.11. The firm had revenue of $71.64 million for the quarter, compared to the consensus estimate of $73.70 million. Harrow had a negative net margin of 1.99% and a positive return on equity of 28.71%. Research analysts expect that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.